These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32055919)

  • 1. CD160 expression on CD8
    Liu S; Zhang W; Liu K; Wang Y
    Cancer Immunol Immunother; 2020 May; 69(5):789-797. PubMed ID: 32055919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
    El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
    J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection.
    Del Rio ML; Nguyen TH; Tesson L; Heslan JM; Gutierrez-Adan A; Fernandez-Gonzalez R; Gutierrez-Arroyo J; Buhler L; Pérez-Simón JA; Anegon I; Rodriguez-Barbosa JI
    Transl Res; 2022 Jan; 239():103-123. PubMed ID: 34461306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanded antigen-experienced CD160
    Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of murine CD160+ CD8+ T lymphocytes.
    Tsujimura K; Obata Y; Matsudaira Y; Nishida K; Akatsuka Y; Ito Y; Demachi-Okamura A; Kuzushima K; Takahashi T
    Immunol Lett; 2006 Jul; 106(1):48-56. PubMed ID: 16764942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral CXCL13
    Wang J; Liang Y; Xue A; Xiao J; Zhao X; Cao S; Li P; Dong J; Li Y; Xu Z; Yang L
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39244216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression.
    Viganò S; Banga R; Bellanger F; Pellaton C; Farina A; Comte D; Harari A; Perreau M
    PLoS Pathog; 2014 Sep; 10(9):e1004380. PubMed ID: 25255144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
    Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
    Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR5
    Bai M; Zheng Y; Liu H; Su B; Zhan Y; He H
    Exp Cell Res; 2017 Dec; 361(1):39-45. PubMed ID: 28965867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD160 Stimulates CD8
    Tan CL; Peluso MJ; Drijvers JM; Mera CM; Grande SM; Brown KE; Godec J; Freeman GJ; Sharpe AH
    Immunohorizons; 2018 Aug; 2(7):238-250. PubMed ID: 31022694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.
    Peretz Y; He Z; Shi Y; Yassine-Diab B; Goulet JP; Bordi R; Filali-Mouhim A; Loubert JB; El-Far M; Dupuy FP; Boulassel MR; Tremblay C; Routy JP; Bernard N; Balderas R; Haddad EK; Sékaly RP
    PLoS Pathog; 2012; 8(8):e1002840. PubMed ID: 22916009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.
    Muscate F; Stetter N; Schramm C; Schulze Zur Wiesch J; Bosurgi L; Jacobs T
    Front Immunol; 2018; 9():2611. PubMed ID: 30483269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
    Sheu BC; Chiou SH; Lin HH; Chow SN; Huang SC; Ho HN; Hsu SM
    Cancer Res; 2005 Apr; 65(7):2921-9. PubMed ID: 15805295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function.
    Rey J; Giustiniani J; Mallet F; Schiavon V; Boumsell L; Bensussan A; Olive D; Costello RT
    Eur J Immunol; 2006 Sep; 36(9):2359-66. PubMed ID: 16917959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.
    D'Addio F; Ueno T; Clarkson M; Zhu B; Vergani A; Freeman GJ; Sayegh MH; Ansari MJ; Fiorina P; Habicht A
    PLoS One; 2013; 8(4):e60391. PubMed ID: 23593209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CD160+ CD8high cytotoxic T cell subset correlates with response to HAART in HIV-1+ patients.
    Nikolova MH; Muhtarova MN; Taskov HB; Kostov K; Vezenkov L; Mihova A; Boumsell L; Bensussan A
    Cell Immunol; 2005 Oct; 237(2):96-105. PubMed ID: 16337931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity.
    Giustiniani J; Marie-Cardine A; Bensussan A
    J Immunol; 2007 Feb; 178(3):1293-300. PubMed ID: 17237375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression.
    Nikolova M; Marie-Cardine A; Boumsell L; Bensussan A
    Int Immunol; 2002 May; 14(5):445-51. PubMed ID: 11978774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CD160 characterization and its association with disease progression in patients with chronic HIV-1 infection].
    Wang L; Xu X; Feng G; Zhang X; Wang F
    Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1559-62. PubMed ID: 25146744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD160 Plays a Protective Role During Chronic Infection by Enhancing Both Functionalities and Proliferative Capacity of CD8+ T Cells.
    Zhang L; Zhang A; Xu J; Qiu C; Zhu L; Qiu C; Fu W; Wang Y; Ye L; Fu YX; Zhao C; Zhang X; Xu J
    Front Immunol; 2020; 11():2188. PubMed ID: 33072082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.